Allied Health Professional · Neurology ·
FDA Label Update: Carbidopa/Levodopa Now Carries a Vitamin B6 Deficiency Warnin…
FDA Label Update: Carbidopa/Levodopa Now Carries a Vitamin B6 Deficiency Warning
In March 2026, the FDA required a new warning on carbidopa/levodopa products regarding vitamin B6 (pyridoxine) deficiency and associated seizures, relevant to anyone managing Parkinson's disease long-term.
Why it matters: carbidopa can interfere with vitamin B6 metabolism, and while this interaction has been recognised for years, the formal warning now flags B6 deficiency as a cause of seizures in patients on long-term therapy, a presentation that is easy to misattribute to disease progression or an unrelated neurological event.
Practical takeaways:
Consider B6 status in patients on long-term carbidopa/levodopa who present with new seizures or unexplained peripheral neuropathy.
Don't assume a new neurological symptom in a Parkinson's patient is automatically disease-related; review the medication list and nutritional status first.
This is a reminder to revisit product labelling periodically, interactions recognised informally for years can still generate new formal warnings worth incorporating into monitoring practice.
Source: FDA Drug Safety Communication, March 2026.